

Criteria and Procedures for Selection of the PhRMA Research Award Recipients

Background

The PhRMA Research Award is a prestigious honor that recognizes advances made across a critical health condition by industry, academia, the patient and caregivers communities and others. It is a celebration of the science, the achievements to date, the possibilities to come and the vital role played by the biomedical research sector in addressing unmet medical needs and public health imperatives.

The 2012 awards will honor innovators in the area of Alzheimer's Disease (AD). The goal is to highlight significant contributions to the diagnosis, treatment and search for a cure for Alzheimer's. Honorees will be nominated from across the spectrum – scientific and academic communities/organizations, biopharmaceutical industry, non-profit organization, patient associations and other entities.

Timetable 2012

July 23, 2012	Deadline for receipt of nominations to PhRMA
August 1, 2012	Voting completed by PhRMA Foundation SAC and vetted by the PhRMA Foundation Board
September 12, 2012	Award presentation

Criteria for Award Nomination (“Excellence in Research” award)

Scope

Nominees must be widely recognized as instrumental players in the field of AD, by having made significant lasting scientific contributions to the mechanistic understanding, diagnosis or treatment of this disease. Contributions can range from basic research on the biological and molecular bases of AD to translational medicine research that has enhanced the developments of therapies. Areas of interest include novel target discovery, biomarker discovery and validation, development of new technologies for early diagnosis, etc.

The “Excellence in Research” Awards includes two categories: “Excellence in Biopharmaceutical Research” and “Excellence in Academic Research”.

Eligibility

- Recognized world-class scientific leadership in field of AD, as demonstrated by publication (first or last author) and citations in high impact-factor journals, invitation to speak and chair at prestigious national and international conferences, and/or holder of patents, relevant to the disease area

- Compelling evidence that work pursued has made a novel, significant, and lasting contribution to understanding the biological and molecular mechanisms underlying the disease, allowing earlier diagnosis, or improving clinical development of therapies
- Nominee must be currently employed and actively working on AD within a research based government agency, academic institution, non-profit organization, or biopharmaceutical company (preference will be given to PhRMA member companies for the “Excellence in Biopharmaceutical Research” track)
- Willingness and ability to attend the Award ceremony and participate in social and media activities planned around the ceremony
- Nominee must reside in the United States

Application Materials

All nominations must include the following materials:

- Completed application form
- Updated copy of resume, curriculum vitae (CV), or biosketch
- Personal statement highlighting strong commitment to research in the field of AD (not to exceed one page).
- Summary of research accomplishments (2 pages maximum in length), including:
 - Research focus
 - Detailed description of two-three major accomplishments and impact of each accomplishment on the knowledge, diagnosis or treatment of the disease
 - List of relevant publications/presentations and/or patents
 - List of previous awards (if any)
- Copies of key selected publications (up to three)
- Three letter of recommendations highlighting the nominee’s excellence and wide recognition in the field of AD

Application Procedures

Please return the application materials, compiled into a single PDF document, directly to Susan Parkinson, (tel: 202-250-5780, or e-mail: sparkinson@phrma.org) by Monday, July 23, 2012. After receiving nominations, the Scientific Advisory Council of the PhRMA Foundation will select the Award winner.